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Abstract Apart from its high affinity receptor TrkA, nerve
growth factor (NGF) can also stimulate the low affinity receptor
p75LNTR and induce a Trk-independent signaling cascade. We
examined the possible involvement of mitogen-activated protein
kinase (MAPK) in this signaling pathway in neuronal cultures of
the cerebellum of P2-aged rats and PCNA cells ; both cell types
express p75LNTR but not TrkA. We found a fast and transient
phosphorylation of p42- and p44-MAPK after stimulation with
NGF or C2-ceramide which proved to be sensitive to inhibition of
MAPK kinase and protein kinase A (PKA). As stimulation with
NGF also activated p21Ras it can be concluded that at least part
of the observed MAPK activation was effected via p21Ras and
via PKA.
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1. Introduction
Nerve growth factor (NGF) and similar neurotrophins have
been extensively characterized as survival and di¡erentiation
factors and as modulators of synaptic strength and neuro-
transmission [1,2]. All these functions could be linked to spe-
ci¢c stimulations of neurotrophin Trk receptors, resulting in
an activation of the mitogen-activated protein kinase
(MAPK) cascade, of phospholipase CQ, and of phosphatidyl-
inositol 3-kinase [3,4].
MAPK is a serine/threonine kinase whose activity is regu-
lated by tyrosine/threonine phosphorylation. The best charac-
terized subtypes, p42-MAPK and p44-MAPK, are speci¢cally
phosphorylated by MAPK kinases which in turn are serine-
phosphorylated by MAPK kinase kinases like Raf-1 [5,6].
p42-MAPK and p44-MAPK are also stimulated by tumor
necrosis factor (TNF) inducing mitogenesis in ¢broblasts [7^
10].
All neurotrophins can also bind to the low a⁄nity neuro-
trophin receptor p75LNTR, and at least NGF is supposed to
induce apoptosis by stimulation of this receptor [11,12].
p75LNTR lacks kinase activity, and only two proteins have
been reported as intracellular binding partners: NRIF, a
zinc ¢nger protein with unknown function [13], and
TRAF6, belonging to the TRAF proteins which bind to
TNF receptors [14]. Functional and structural similarity of
p75LNTR and TNF receptors suggests similar signaling, and
Dobrowsky et al. [15] could demonstrate activation of the
sphingomyelinase pathway after p75LNTR stimulation. Re-
cently Boone and co-workers [7] observed activation of
MAPK by the receptor p55 of TNF with participation of
the receptor’s ‘death domain’ ; an analogous participation of
the death domain of p75LNTR in the signaling of this receptor
may be conjectured.
In the present study we wanted to investigate if p75LNTR
stimulation involves MAPK activation. We chose neuronal
cultures of the cerebellum of P2-aged rats (cerebellar granule
cells, CGC). At this stage of development these neurons pro-
duce relatively high levels of p75LNTR while no TrkA is de-
tectable. We compared the obtained results with those on
PCNA cells (L-¢broblasts transfected stably with p75LNTR
cDNA [16]) where p75LNTR signaling can be analyzed without
interference from TrkA signaling. We found that stimulation
of p75LNTR with NGF or application of C2-ceramide leads to
an activation of MAPK via activated MAPK kinase which in
turn probably was activated by p21Ras since NGF stimula-
tion also increased activated p21Ras.
2. Materials and methods
2.1. Materials
Dulbecco’s modi¢ed Eagle’s medium, glutamine, trypsin^EDTA,
and penicillin/streptomycin were obtained from Gibco (Eggenstein,
Germany), fetal calf serum from Greiner (Frickenhausen, Germany)
and 2.5S L-NGF from Alomone (London, UK). Antibodies, used in
the indicated dilution, were obtained from the following sources: anti-
phospho-MAPK (1:1000): New England Biolabs (Schwalbach, Ger-
many); anti-phosphotyrosine (1:2000): Upstate Biotechnology/Bio-
mol (Hamburg, Germany); anti-p75LNTR (MC192, 800 ng/ml): Roche
Diagnostics (Mannheim, Germany); anti-mouse horseradish peroxi-
dase (HRP; 1:2000): Sigma (Munich, Germany). [32P]Phosphatidic
acid was purchased from Du-Pont NEN (Zaventem, Belgium). C2-
ceramide was from Biomol, PKI-tide from Bachem (Heidelberg, Ger-
many), protein A-Sepharose from Sigma/Fluka (Munich, Germany),
and IBMX and all other agents were obtained from Sigma (Munich,
Germany) if not otherwise indicated.
2.2. Cell culture
Primary cultures of CGC were prepared from Wistar rats at the
developmental stage P2 as described for hippocampal neurons [17].
PCNA cells (a kind gift from E.M. Shooter, Stanford, CA, USA) were
grown as a monolayer in Dulbecco’s modi¢ed Eagle’s medium/10%
fetal calf serum/1 mM Glutamax. PC12 cells (H. Thoenen, Mar-
tinsried, Germany) were grown in Dulbecco’s modi¢ed Eagle’s me-
dium/10% fetal calf serum/5% horse serum/1 mM Glutamax. For ex-
periments, all types of cells were seeded on 35 mm dishes (Sarstedt,
Nu«mbrecht, Germany) at a density of 5U105 and on 24 well plates at
2.5U105 cells per well and used for experiments on the third day in
culture.
2.3. RT-PCR (reverse transcriptase PCR)
For the detection of TrkA and p75LNTR expression, RNA was iso-
lated, transcribed with Superscript (Gibco BCR, Eggenstein, Ger-
many) and oligo-dT primer (24-mer) into cDNA, and PCR was per-
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formed using the primers 5P-AGAAGAAGGACGAAACACCT-3P
and 5P-TCACTGAAGTACTGTGGGTT-3P for TrkA detection and
5P-CGCCATGAGGAGGGGAGGTG-3P and 5P-AGACCTTGGGA-
TCCATCGAC-3P for p75LNTR detection. The PCR program for TrkA
(hot start) was: 5 min 95‡C; 30 cycles of 95‡C (1 min), 60‡C (1 min,
+0.1‡/cycle), 72‡C (1 min); 10 min 72‡C. An analogous program was
executed for p75LNTR but 40 cycles with an annealing temperature of
62‡C (1 min, +0.1‡/cycle) were used.
2.4. Stimulation, lysis, immunoprecipitation, analysis by Western blot
and analysis of p21Ras activation
Cells were stimulated by adding neurotrophins or agents (dissolved
in medium) to the cells (without changing the medium). Inhibitors
were added 30 min prior to stimulation. For the sake of brevity, the
expression ‘after stimulation’ will be used instead of ‘after the start of
stimulation’.
After stimulation cells were placed on ice and lysed with 60 Wl per
35 mm dish and 30 Wl per well of 24 well plates with a bu¡er con-
taining 50 mM Tris^HCl at pH 7.4, 150 mM NaCl, 40 mM NaF,
5 mM EDTA, 1 mM Na3VO4, 1% (v/v) Nonidet P40, 0.1% (w/v)
sodium deoxycholate, 0.1% (w/v) sodium dodecyl sulfate (SDS),
1 mM phenylmethylsulfonyl £uoride for 10 min (4‡C) on a shaker.
Lysates were centrifuged for 10 min at 14 000 rpm (4‡C), and the
supernatant was frozen for further use at 320‡C.
For immunoprecipitation, equal amounts of protein were incubated
with the antibody at concentrations suggested by the suppliers for 4 h
at 4‡C on a shaker. Protein A coupled to Sepharose was added at a
concentration of 100 Wg/ml and the incubation was continued over-
night at 4‡C; the antibody^protein^protein A complex was separated
by centrifugation (14 000 rpm, 4‡C, 5 min), washed once with 500 mM
LiCl in 100 mM Tris^HCl, pH 7.4, and twice in 10 mM Tris^HCl, pH
7.4, then denatured in Laemmli sample bu¡er (10 min at 95‡C) and
analyzed with SDS-PAGE.
Equal amounts of protein (10^15 Wg/slot) were analyzed with SDS-
PAGE. Western blots were performed as suggested by the suppliers of
the antibodies, and detected with enhanced chemiluminescence (Phar-
macia/Amersham Corp., Freiburg, Germany). For semiquanti¢cation,
Western blots were scanned and densitometrically analyzed with the
program TINA 2.09 (Raytest IsotopenmeMgera«te; Straubenhardt,
Germany).
Analysis of p21Ras activation was performed in PCNA cells or
CGC, seeded at a density of 106 per 35 mm dish on day 2 prior to
experiments, according to Valius and Kazlauska [18]. The amount of
radioactivity present in GTP and GDP was quanti¢ed with a phos-
pho-imager (BioImager Bas 100C) and evaluated with the program
TINA 2.09.
3. Results and discussion
MAPK activation plays a signi¢cant role in the signaling of
neurotrophins. Since MAPK is transferred into the nucleus
soon after activation, cytosolic as well as nuclear targets can
be in£uenced by the enzyme. Typically tyrosine kinase-in-
duced MAPK activation will be sustained over hours, even
days. In the present study we describe activation of MAPK
after stimulation of p75LNTR with NGF which is relatively fast
and short-lived in contrast with Trk-mediated activation.
3.1. MAPK is activated after stimulation of p75LNTR with NGF
We used PCNA cells and CGC (developmental stage P2)
for our experiments. With RT-PCR we ensured that both cell
types did not express TrkA (Fig. 1). In PCNA cells and
K252a-pretreated CGC cultures, p44-MAPK and p42-
MAPK (in the following collectively referred to as MAPK)
were activated by NGF-mediated stimulation of p75LNTR
within 3 min (PCNA, Fig. 2A) and 5 min (CGC, Fig. 2B).
This e¡ect subsided within 30^60 min to control levels. In
CGC pretreatment with K252a was necessary to inhibit acti-
vation of MAPK via Trk receptors which are stimulated by
other neurotrophins (BDNF or NT-3) spontaneously released
within the culture.
MAPK activation can be a¡ected by the activation of
sphingomyelinase [9,10]. p75LNTR is known to activate sphin-
gomyelinase and elevate ceramide levels [15]; the receptor-
mediated onset of ceramide production takes place 10^15
min [15,19] after stimulation. Since we observed a fast
MAPK activation after NGF stimulation (3^5 min) ceramide
cannot be the only cause of MAPK activation during p75LNTR
signaling. To examine how ceramide in£uences this MAPK
activation we stimulated PCNA cells and CGC with C2-ce-
ramide, a membrane-passing, short form of the natural long
acyl chain ceramide. In PCNA cells C2-ceramide caused stim-
ulation of MAPK similar to NGF (Fig. 2A) but with a slight
temporal shift. With CGC, however, the observed activation
pattern was more complex. Without inhibition of Trk recep-
tors by K252a we ¢rst observed a slight reduction of activated
MAPK (5^15 min), then levels comparable to controls, and
after about 1 h a distinct reduction. We performed a semi-
quanti¢cation using densitometric analysis of the Western
blots. Compared to the control (100% þ 32), p44-MAPK
was reduced to 57% ( þ 12) at 15 min, slightly increased to
158% ( þ 19) at 60 min, and decreased again to 60% ( þ 23)
and 45% ( þ 15) at 2 and 4 h, respectively. Treatment with
K252a resulted in a peak at 5 min (137% þ 29) and in a pro-
nounced elevation of activated MAPK after 30 min
(283% þ 34), and subsided after 1 and 4 h to 160% ( þ 41)
and 127% ( þ 38), respectively. These data (obtained in four
independent experiments) suggest an interference between
TrkA and sphingomyelin pathway, which requires separate
investigation. Several authors [20,21] described inhibitory
e¡ects of Trk signaling on p75LNTR, and conversely inhibition
of TrkA activation by serine phosphorylation via C2-ceramide
has been described [22]. While the same authors [22] recently
reported a ceramide-induced activation of TrkA-tyrosine
autophosphorylation in PC12 cells after longer treatment
(s 1 h) with C2-ceramide [23], our data for CGC (cells that
express TrkB and TrkC but not TrkA) do not support this
result as we observed inhibition of MAPK activation after 1 h
of treatment with C2-ceramide and Trk stimulation should
induce MAPK activation.
3.2. Some elements of the mechanism of MAPK
phosphorylation
To analyze the mechanism of MAPK activation via
p75LNTR, we examined the involvement of MAPK kinase
which could be blocked with PD-098059. This pretreatment
nearly completely inhibited NGF- and C2-ceramide-mediated
MAPK activation (Fig. 2A). Therefore certainly MAPK ki-
nase steps between p75LNTR and MAPK. As this observation
indicated a Ras-Raf-dependent pathway we studied a possible
Fig. 1. RT-PCR of TrkA and p75LNTR was performed with mRNA
of PC12 cells (serving as a positive control expressing TrkA and
p75LNTR), PCNA cells and CGC. The PCR products are marked by
arrows.
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interaction of p75LNTR with p21Ras. Using a very sensitive
radioactive assay we observed a p21Ras activation which was
similar to that in positive controls where PCNA cells were
stimulated with platelet-derived growth factor (PDGF),
known for signaling via p21Ras [18], and CGC with neuro-
trophin-4 (Table 1).
In PC12 cells (with TrkA and p75LNTR) Volonte¤ and co-
authors [24] observed an association of activated MAPK with
p75LNTR mediated by TrkA. For our experiments we can rule
out such an interaction between TrkA, p75LNTR and MAPK
as there was no TrkA. We could co-precipitate phosphoryl-
ated MAPK and tyrosine-phosphorylated p75LNTR (Fig. 3)
which suggests a common compartment or even a complex
of the two proteins although p75LNTR is tyrosine-phosphoryl-
ated and certainly cannot be phosphorylated by MAPK, a
serine/threonine kinase.
Other protein kinases might possibly be involved in MAPK
activation. Impey et al. [25] reported that MAPK phospho-
rylation can depend on protein kinase A (PKA) and that
translocation of MAPK into the nucleus is reduced by PKA
inhibitors. Indeed, we found a reduced and delayed MAPK
phosphorylation after PKA inhibition (peak at 15 min after
stimulation with NGF) and elevated activation after applica-
tion of IBMX, which activates PKA (by inhibiting phospho-
diesterase), suggesting PKA as upstream activator of MAPK
(Fig. 4); PKA-mediated MAPK activation might be con-
nected with translocation of MAPK into the nucleus.
We conclude that stimulation of p75LNTR with NGF or
application of C2-ceramide leads to an activation of MAPK
requiring activated MAPK kinase. As p21Ras activity also
increases after stimulation of p75LNTR, the receptor signaling
probably proceeds via p21Ras to activation of MAPK kinase
and MAPK. Part of the observed MAPK activation should be
e¡ected via PKA.
Fig. 2. In PCNA cells (A) and CGC (B), NGF and C2-ceramide induce MAPK phosphorylation. Cells were stimulated over the indicated time
(min) either with NGF (100 ng/ml) or with C2-ceramide (100 WM); MAPK inhibitor PD-098059 (10 WM) or tyrosine kinase inhibitor K252a
(100 nM) were added 30 min prior to stimulation. +/3 signs indicate application/absence of the respective agent. Cells were lysed and equal
amounts of protein were analyzed by Western blotting with monoclonal phospho-speci¢c MAPK antibodies. The results shown are representa-
tive for four independent experiments.
Table 1
NGF activates p21Ras via p75LNTR
Treatment PCNA (% GTP) CGC (% GTP)
0 min NGF 4.77 þ 0.78 (n = 3) 12.16 þ 2.76 (n = 2)
2 min NGF 8.54 þ 1.30* (n = 3) n.d.
5 min NGF 6.36 þ 2.67 (n = 3) 17.39 þ 6.22 (n = 2)
5 min PDGF 12.49 þ 2.00 (n = 2) n.d.
5 min NT-4 n.d. 35.44 þ 10.44 (n = 2)
K252a/0 min NGF 4.47 þ 0.98 (n = 3) 15.46 þ 1.17 (n = 2)
K252a/2 min NGF 10.67 þ 1.21 (n = 2) 18.90 þ 2.26 (n = 2)
K252a/5 min NGF 7.36 þ 1.76 (n = 3) 26.88 þ 4.92 (n = 2)
PCNA cells and CGC were stimulated with NGF (100 ng/ml),
PDGF (10 ng/ml) and NT-4 (10 ng/ml) for the indicated time and
p21Ras activation was measured as described. Results are presented
as percentage of GTP to total guanine nucleotides. Some cultures
were pretreated with K252a (100 nM). n.d. = not determined;
*P6 0.05 to control (t-test).
Fig. 3. The receptor p75LNTR is phosphorylated by NGF stimula-
tion and can be co-precipitated with phosphorylated MAPK. PCNA
cells were stimulated with NGF (100 ng/ml) for 5 min. p75LNTR was
precipitated with the monoclonal antibody MC192 from the cell ly-
sate and analyzed by Western blotting with a monoclonal phospho-
tyrosine-speci¢c antibody.
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Fig. 4. In£uence of PKA on NGF-induced phosphorylation of
MAPK. PCNA cells were stimulated with NGF (100 ng/ml) over
the indicated time (min). For inhibition of PKA, PKI-tide (100 WM)
was added 30 min prior to stimulation. To activate PKA the cells
were stimulated with the inhibitor of phosphodiesterase IBMX (200
WM). The cells were lysed and equal amounts of protein were ana-
lyzed by Western blotting with monoclonal phospho-speci¢c MAPK
antibodies. The results shown are representative for two independent
experiments.
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